293 related articles for article (PubMed ID: 31969678)
21. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.
Peinemann F; Bartel C; Grouven U
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006407. PubMed ID: 23881658
[TBL] [Abstract][Full Text] [Related]
22. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.
Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I
Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982
[TBL] [Abstract][Full Text] [Related]
23. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
24. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J
Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642
[TBL] [Abstract][Full Text] [Related]
25. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
26. Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors.
Shiratori S; Sugita J; Fuji S; Aoki J; Sawa M; Ozawa Y; Hashimoto D; Matsuoka KI; Imada K; Doki N; Ashida T; Ueda Y; Tanaka M; Sawayama Y; Ichinohe T; Terakura S; Morishima S; Atsuta Y; Fukuda T; Teshima T
Bone Marrow Transplant; 2021 Sep; 56(9):2231-2240. PubMed ID: 33963304
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network Meta-Analysis.
Gagelmann N; Ayuk F; Wolschke C; Kröger N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2184-2191. PubMed ID: 28864138
[TBL] [Abstract][Full Text] [Related]
28. Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation.
Remberger M; Mattsson J; Ringdén O
Pediatr Transplant; 2001 Aug; 5(4):285-92. PubMed ID: 11472608
[TBL] [Abstract][Full Text] [Related]
29. [Antithymocyte globulin for graft-versus-host disease prophylaxis, past, present and future].
Shiratori S
Rinsho Ketsueki; 2022; 63(5):412-422. PubMed ID: 35662166
[TBL] [Abstract][Full Text] [Related]
30. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
Soiffer RJ; Kim HT; McGuirk J; Horwitz ME; Johnston L; Patnaik MM; Rybka W; Artz A; Porter DL; Shea TC; Boyer MW; Maziarz RT; Shaughnessy PJ; Gergis U; Safah H; Reshef R; DiPersio JF; Stiff PJ; Vusirikala M; Szer J; Holter J; Levine JD; Martin PJ; Pidala JA; Lewis ID; Ho VT; Alyea EP; Ritz J; Glavin F; Westervelt P; Jagasia MH; Chen YB
J Clin Oncol; 2017 Dec; 35(36):4003-4011. PubMed ID: 29040031
[TBL] [Abstract][Full Text] [Related]
31. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy analysis of anti-thymocyte globulin regimens with different timing strategies for matched sibling donor hematopoietic stem cell transplantation].
Du JS; Wang HT; Dou LP; Wang N; Li F; Jin XS; Liu DH
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):660-666. PubMed ID: 37803840
[No Abstract] [Full Text] [Related]
33. In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation.
Nachbaur D; Eibl B; Kropshofer G; Meister B; Mitterschiffthaler A; Schennach H; Fischer G; Kopp M; Gunsilius E; Gastl G
J Hematother Stem Cell Res; 2002 Aug; 11(4):731-7. PubMed ID: 12201962
[TBL] [Abstract][Full Text] [Related]
34. Preconditioning Absolute Lymphocyte Count and Transplantation Outcomes in Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Reduced-Intensity Conditioning and Antithymocyte Globulin Treatment.
Woo GU; Hong J; Kim H; Byun JM; Koh Y; Shin DY; Kim I; Yoon SS
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1855-1860. PubMed ID: 32561338
[TBL] [Abstract][Full Text] [Related]
35. Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia.
Chen X; Wei J; Huang Y; He Y; Yang D; Zhang R; Jiang E; Ma Q; Zhai W; Yao J; Zhang G; Feng S; Han M
Biol Blood Marrow Transplant; 2018 Jan; 24(1):86-90. PubMed ID: 29032265
[TBL] [Abstract][Full Text] [Related]
36. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin.
Finke J; Schmoor C; Lang H; Potthoff K; Bertz H
J Clin Oncol; 2003 Feb; 21(3):506-13. PubMed ID: 12560442
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.
Yuan J; Pei R; Su W; Cao J; Lu Y
Oncotarget; 2017 Feb; 8(7):10871-10882. PubMed ID: 28107198
[TBL] [Abstract][Full Text] [Related]
39. Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia.
Huang Z; Yan H; Teng Y; Shi W; Xia L
Front Immunol; 2022; 13():1017850. PubMed ID: 36458000
[TBL] [Abstract][Full Text] [Related]
40. [Antithymocyte globulin for GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation].
Shiratori S
Rinsho Ketsueki; 2021; 62(8):1265-1274. PubMed ID: 34497215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]